This week’s ARCS sector update covers three major developments shaping Australia’s medtech and pharmaceutical landscape.

We unpack the AMR 2026 Summit in Sydney and the release of the Sixth AURA Report, highlighting why antimicrobial resistance is now an economic and national resilience issue.

We examine the surge in PBS activity, with more than 20 medicines nearing listing decisions, and what this means for oncology, biosimilars and HTA reform.

And we explore Australia’s advanced therapies momentum, as Peter MacCallum Cancer Centre doses the first patient in a locally developed CD19 CAR T trial.

What do these shifts mean for regulatory, clinical, market access and quality professionals?

Listen now to stay ahead of the signals shaping 2026.